Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 5S ribosomal pseudogene 232 is a member of the rRNA pseudogene family, derived from the 5S ribosomal RNA gene through gene duplication or retrotransposition events[2][6]. Unlike functional 5S rRNA, which plays a key structural role in ribosome assembly and protein synthesis[1][3][5], this pseudogene does not produce functional RNA and is considered genomically inactive. rRNA pseudogenes are generally retained in the genome due to sequence homology but lack the ability to contribute to ribosome structure or mediate cellular functions[2][6]. Some pseudogenes in other families can exert regulatory impacts on gene expression; however, no such role is described for RNA5SP232.\nIf additional details or specifics about function or disease association are needed, experimental confirmation would be required, as no clear evidence supports its activity.
Not applicable. There are no drugs targeting RNA5SP232 or other rRNA pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 5S ribosomal pseudogene 232 (RNA5SP232).